You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
藥明巨諾-B(02126.HK):在EULAR 2024公佈瑞基奧侖賽注射液用於治療活動性系統性紅斑狼瘡中國成人患者中的初步臨牀數據
格隆匯 05-30 16:35

格隆匯5月30日丨藥明巨諾-B(02126.HK)發佈公吿,在2024歐洲風濕病學大會(“EULAR 2024”)上公佈了瑞基奧侖賽注射液在中國成人活動性系統性紅斑狼瘡(“SLE”)患者中的最新臨牀數據。

根據披露,系統性紅斑狼瘡是一種慢性自身免疫性疾病,可引起全身多臟器和組織受損。據估算,我國系統性紅斑狼瘡患者約有100萬人,總數位居全球第一,發病率位居第二。目前系統性紅斑狼瘡的傳統療法包括皮質類固醇、抗瘧藥物、非甾體抗炎藥物、細胞毒性藥物以及免疫抑制╱調節劑,但傳統治療因長期耐受性差,影響治療效果,從而導致患者疾病控制不佳造成器官損害,進一步影響預後和長期生存。尤其是需要大劑量激素及免疫抑制劑進行治療的中重度活動性SLE患者。

藥明巨諾首席醫學官Mark J. Gilbert博士表示:“儘管近年來針對SLE的新型生物製劑和治療手段相繼出現,仍有很多SLE患者對目前的治療方法無反應,目前還沒有可靠的治療策略達到無藥物緩解甚至治癒該疾病。這項研究的短期隨訪資料已初步顯示,瑞基奧侖賽注射液低劑量在SLE患者中具有良好的安全性,並能夠帶來深度緩解,使患者達到低疾病活動狀態甚至無藥物緩解,其在SLE 治療中的應用前景值得期待。”

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account